Develops and produces active ingredients extracted from microalgae
Advised on Recapitalization of Company
Advised on the €12.8m capital increase completed by Fermentalg
Fermentalg successfully completed a €12.8 million capital increase designed to further its 2024-2026 strategic plan and consolidate its position as the European leader in sustainable solutions based on marine microalgae biotechnology. The HuvePharma group, European leader in precision fermentation in the animal and human health sectors, and a new industrial partner of Fermentalg since December 2023, invested €7.5 million, becoming a reference shareholder.
An expert in the research and bioindustrial exploitation of microalgae, Fermentalg aims to offer sustainable solutions and innovative products that contribute to the development of healthy, natural and high-performance products. It develops, produces and markets sustainable solutions and active ingredients derived from microalgae, for nutrition, health and the environment.
DegroofPetercam – IMAP France acted as financial adviser to Fermentalg, characterizing the company's financial needs, seeking potential financial and strategic partners, and structuring a market transaction with French banks for the execution of the Private Placement.
We love to hear from you. Our team is always here to chat.
Contact form
Thank you for your interest in IMAP. Please use the form below to tell us more about your current situation and we’ll be sure to have the right professional get back to you as soon as possible.
